GlassScriptPhysician profile
Thomas N Robeson
NPI 1982641171
$33,776.79
in general payments reported to CMS, 2019-2025
83 companies · $2,893 in 2025
The $2,893 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,311 · 2020: $4,074 · 2021: $9,576 · 2022: $3,469 · 2023: $3,575 · 2024: $2,879 · 2025: $2,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,339 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,338.60 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $5,323.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $3,694.45 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $3,566.09 | 2019-2025 | Farxiga, Fasenra, Airsupra |
| Abbvie INC. | $2,385.91 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $2,084.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,407.13 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,364.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,313.21 | 2019-2025 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,107.07 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $946.37 | 2019-2025 | Xifaxan |
| Radius Health, INC. | $728.14 | 2019-2025 | Tymlos |
| Esperion Therapeutics, INC. | $700.33 | 2020-2025 | Nexletol |
| Astellas Pharma US INC | $632.86 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $556.48 | 2019-2021 | |
| Allergan, INC. | $518.23 | 2019-2021 |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Robeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.